(IVA) Inventiva - Overview
Stock: Lanifibranor, Odiparcil, TGF-β
| Risk 5d forecast | |
|---|---|
| Volatility | 80.2% |
| Relative Tail Risk | -11.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.45 |
| Alpha | 137.82 |
| Character TTM | |
|---|---|
| Beta | 0.737 |
| Beta Downside | 1.163 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.03% |
| CAGR/Max DD | 0.15 |
Description: IVA Inventiva January 26, 2026
Inventiva S.A. (NASDAQ: IVA) is a French clinical-stage biopharma focused on oral small-molecule therapies, most notably Lanifibranor, a pan-PPAR agonist being evaluated in the NATiV3 Phase 3 trial for metabolic dysfunction-associated steatohepatitis (MASH). The company also advances Odiparcil for mucopolysaccharidoses and a pre-clinical TGF-β program targeting idiopathic pulmonary fibrosis.
As of the latest Q3 2025 shareholder update, Lanifibranor’s interim analysis showed a statistically significant 30 % relative reduction in fibrosis progression versus placebo (p = 0.021) and met the key secondary endpoint of NASH resolution without worsening of fibrosis. Inventiva reported €150 million in cash and marketable securities at 31 Dec 2025, giving it an estimated runway into Q4 2027 assuming current burn of €30 million per quarter.
The MASH market is expanding rapidly; consensus forecasts from BloombergNEF place the global addressable market at ≈ $12 billion by 2028, driven by rising obesity rates and limited approved therapies. Concurrently, the broader biotech sector has benefited from a 12 % YoY increase in R&D capital inflows in Europe (2024-2025), supporting companies with late-stage pipelines like Inventiva.
For a deeper quantitative comparison of Inventiva’s valuation metrics against peers, you might find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -409.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.79 > 0.02 and ΔFCF/TA 222.9 > 1.0 |
| NWC/Revenue: 695.2% < 20% (prev -49.21%; Δ 744.4% < -1%) |
| CFO/TA -0.78 > 3% & CFO -139.8m > Net Income -409.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (108.8m) vs 12m ago 109.4% < -2% |
| Gross Margin: 89.60% > 18% (prev 0.96%; Δ 8864 % > 0.5%) |
| Asset Turnover: 15.04% > 50% (prev 100.7%; Δ -85.67% > 0%) |
| Interest Coverage Ratio: -17.86 > 6 (EBITDA TTM -384.2m / Interest Expense TTM 21.9m) |
Altman Z'' -15.00
| A: 0.64 (Total Current Assets 172.4m - Total Current Liabilities 58.5m) / Total Assets 178.5m |
| B: -0.99 (Retained Earnings -175.9m / Total Assets 178.5m) |
| C: -3.59 (EBIT TTM -391.5m / Avg Total Assets 109.0m) |
| D: -2.99 (Book Value of Equity -561.5m / Total Liabilities 187.9m) |
| Altman-Z'' Score: -26.31 = D |
Beneish M 1.00
| DSRI: 68.26 (Receivables 22.8m/809.0k, Revenue 16.4m/39.7m) |
| GMI: 1.07 (GM 89.60% / 96.03%) |
| AQI: 0.17 (AQ_t 0.01 / AQ_t-1 0.07) |
| SGI: 0.41 (Revenue 16.4m / 39.7m) |
| TATA: -1.51 (NI -409.1m - CFO -139.8m) / TA 178.5m) |
| Beneish M-Score: 49.93 (Cap -4..+1) = D |
What is the price of IVA shares?
Over the past week, the price has changed by +9.40%, over one month by +4.98%, over three months by +73.97% and over the past year by +146.35%.
Is IVA a buy, sell or hold?
- StrongBuy: 6
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the IVA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 15.9 | 135.3% |
| Analysts Target Price | 15.9 | 135.3% |
IVA Fundamental Data Overview February 20, 2026
P/S = 82.0179
P/B = 2.1025
Revenue TTM = 16.4m EUR
EBIT TTM = -391.5m EUR
EBITDA TTM = -384.2m EUR
Long Term Debt = 51.6m EUR (from longTermDebt, last quarter)
Short Term Debt = 5.53m EUR (from shortTermDebt, last quarter)
Debt = 57.1m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -64.9m EUR (from netDebt column, last quarter)
Enterprise Value = 408.9m EUR (473.9m + Debt 57.1m - CCE 122.1m)
Interest Coverage Ratio = -17.86 (Ebit TTM -391.5m / Interest Expense TTM 21.9m)
EV/FCF = -2.92x (Enterprise Value 408.9m / FCF TTM -140.2m)
FCF Yield = -34.29% (FCF TTM -140.2m / Enterprise Value 408.9m)
FCF Margin = -855.7% (FCF TTM -140.2m / Revenue TTM 16.4m)
Net Margin = -2497 % (Net Income TTM -409.1m / Revenue TTM 16.4m)
Gross Margin = 89.60% ((Revenue TTM 16.4m - Cost of Revenue TTM 1.70m) / Revenue TTM)
Gross Margin QoQ = 61.74% (prev none%)
Tobins Q-Ratio = 2.29 (Enterprise Value 408.9m / Total Assets 178.5m)
Interest Expense / Debt = 17.06% (Interest Expense 9.74m / Debt 57.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -309.3m (EBIT -391.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.95 (Total Current Assets 172.4m / Total Current Liabilities 58.5m)
Debt / Equity = -6.11 (negative equity) (Debt 57.1m / totalStockholderEquity, last quarter -9.35m)
Debt / EBITDA = 0.17 (negative EBITDA) (Net Debt -64.9m / EBITDA -384.2m)
Debt / FCF = 0.46 (negative FCF - burning cash) (Net Debt -64.9m / FCF TTM -140.2m)
Total Stockholder Equity = -75.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -375.4% (out of range, set to none)
RoE = 542.4% (negative equity) (Net Income TTM -409.1m / Total Stockholder Equity -75.4m)
RoCE = 1643 % (out of range, set to none) (EBIT -391.5m / Capital Employed (Equity -75.4m + L.T.Debt 51.6m))
RoIC = 7071 % (out of range, set to none) (NOPAT -309.3m / Invested Capital -4.37m)
WACC = 9.15% (E(473.9m)/V(531.0m) * Re(8.63%) + D(57.1m)/V(531.0m) * Rd(17.06%) * (1-Tc(0.21)))
Discount Rate = 8.63% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 49.56%
Fair Price DCF = unknown (Cash Flow -140.2m)
EPS Correlation: -51.27 | EPS CAGR: 23.58% | SUE: -0.02 | # QB: 0
Revenue Correlation: 60.55 | Revenue CAGR: 442.4% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=-1.71 | Chg30d=-0.530 | Revisions Net=-3 | Growth EPS=+26.5% | Growth Revenue=-70.2%